DOCSLIB.ORG

Determination of Dapiprazole Hydrochloride in the Presence of Process and Degradation Impurities by a Validated Stability Indicating RP-HPLC Method

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Determination of Dapiprazole Hydrochloride in the Presence of Process and Degradation Impurities by a Validated Stability Indicating RP-HPLC Method Asian Journal of Chemistry; Vol. 25, No. 9 (2013), 4820-4824 http://dx.doi.org/10.14233/ajchem.2013.14114 Determination of Dapiprazole Hydrochloride in the Presence of Process and Degradation Impurities by a Validated Stability Indicating RP-HPLC Method * K. JAYA PRASANTHI and B. SYAMA SUNDAR Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur-522 510, India *Corresponding author: E-mail: [email protected] (Received: 27 May 2012; Accepted: 8 March 2013) AJC-13080 Dapiprazole hydrochloride is an α-adrenergic blocking agent. Chemically, it is 5,6,7,8-tetrahydro-3-[2-(4- o-tolyl-1-piperazinyl)ethyl]-s- triazolo[4,3-a]pyridine hydrochloride, which is widely used in ophthalmic practice. A stability-indicating RP-HPLC method has been developed and validated which can separate and accurately quantitate dapiprazole related compounds. The method was successfully validated in accordance to ICH guidelines acceptance criteria for system suitability, specificity, linearity, range, precision, accuracy, limits of detection and quantification for the impurities and robustness, following the ICH guidelines. Therefore, the proposed method was suitable for the simultaneous determination of dapiprazole and its process related and degreadation impurities. Finally, the applicability of the method was evaluated in commercial dosage form analysis as well as in stability studies. Key Words: Dapiprazole, Degradants, Validation, Stability indicating HPLC method. INTRODUCTION of dapiprazole in the drug substance. To the best of our know- ledge, no analytical methods are currently available to separate Dapiprazole hydrochloride is an α-adrenergic blocking and quantitate the known process related compounds of 1,2 agent . Chemically, it is 5,6,7,8-tetrahydro-3-[2-(4-o-tolyl- dapiprazole API. Furthermore, there is no stability-indicating 3 1-piperazinyl)ethyl]-s-triazolo[4,3-a] pyridine hydrochloride HPLC method reported in the literature that can adequately (empirical formula C19H27N5·HCl, m.w. 361.93). It is a sterile, separate and accurately quantitate dapiprazole and degradation white, lyophilized powder soluble in water. Dapiprazole hydro- compounds. Chemical structures of dapiprazole and it process chloride ophthalmic solution is indicated in the treatment of related impurity was shown below. (Fig. 1(a)) and the synthetic iatrogenically induced mydriasis produced by adrenergic route, in which the process related impurity has been formed, 4 (phenylephrine) or parasympatholytic (tropicamide) agents . is shown in Fig. 1(b). The aim of this paper was to develop validate a simple and reliable HPLC-UV method for the simultaneous determination EXPERIMENTAL of dapiprazole and its process related impurity-A. Besides the Waters Alliance 2695 separation module (Waters Corpo- simple route of synthesis for dapiprazole, we have observed a ration, Milford, USA) equipped with 2489 UV/visible detector potential impurity (Imp-A) in our synthetic process and some or 2998 PDA detector (for specificity and forced degradation unknown impurities in forced degradation. Hence, a stability- studies) with Empower 2 software was used for the analysis. indicating HPLC method for determination of dapiprazole in The chromatographic and the integrated data were recorded presence of process and degradation impurities was developed using HP-Vectra (Hewlett Packard, Waldbronn, Germany) and validated as per International Conference on Harmonization computer system. Chromatographic separation of dapiprazole (ICH) guidelines. This manuscript describes the development and its process related impurity was achieved on Inertsil ODS and validation, in accordance with ICH guidelines, of a rapid, C18-3V (250 mm × 4.6 mm, 5 µ particle size). The pH measu- economical, precise and accurate stability-indicating isocratic rements were carried out with Elico, model LI 120, pH meter reversed-phase HPLC method for analysis of dapiprazole in equipped with a combined glass-calomel electrode calibrated the presence of its process related impurity. This paper also using standard buffer solutions of pH 4.0, 7.0 and 9.2. deals with the forced degradation of dapiprazole under the All the reagents were of analytical-reagent grade unless stress conditions acidic and basic hydrolysis, oxidation, heat stated otherwise. Glass-distilled and deionized water (Nanopure, and light and validation of the method for accurate quantification Barnstead, USA), HPLC-grade acetonitrile, potassium dihydrogen Vol. 25, No. 9 (2013) Determination of Dapiprazole Hydrochloride in the Presence of Process and Degradation Impurities 4821 orthophosphate, sodium hydroxide, hydrochloric acid, hydrogen Forced degradation solutions: Weigh accurately 25 mg peroxide and orthophosphoric acid (SD Fine Chem, Mumbai, of dapiprazole sample and transfer into a 50 mL volumetric India) were used. Active pharmaceutical ingredient of flask and make up the volume up to 50 mL with mobile phase dapiprazole (reference standard) and its process related subs- to get the concentration of 500 µg/mL of dapiprazole standard tances viz. Impurity, 1-(o-tolyl)-piperizine were a kind of gift solution. from Hetero Drugs Pvt. Ltd., Hyderabad. Method validation: Validation of the developed method Chromatographic conditions: Separation was achieved for the determination of dapiprazole and its process related on a Inertsil-ODS-C18-3VS column (250 mm × 4.0 mm, 5 µm) mpurity was performed according to the ICH guidelines with using an isocratic mode by the mobile phase consists of a standards and API. Thus, system suitability along with method mixture of buffer and acetonitrile in the ratio of 85:15 v/v was selectivity, specificity, linearity, range, precision, accuracy, at pH-3.2 adjusted with 10 % orthophosphoric acid in water. limits of detection and quantification for the impurities, short The column was then re-equilibrated for 10 min with mobile term and long term stability of the analytes in the prepared phase. The flow rate of the mobile phase was 1 mL/min and solutions and robustness were demonstrated. the total elution time, including the column re-equilibration, System suitability: The system suitability was conducted was ca. 0.5 h. The UV detection wavelength was carried at using 1.5 % (w/w) of the impurity spiked to dapiprazole (3.0 205 nm. The injection volume was 20 µL and experiments mg/mL) and evaluated by making three replicate injections. were conducted at ambient temperature. The system was suitable for use if the tailing factors for Preparation of system suitability solution (standard dapiprazole and its impurity were < 1.55 (observed value is solution): Standards of dapiprazole and its process related 1.06) and the resolution was > 1.90 (observed value is 7.33). impurity (20 mg each) were accurately weighed, transferred Specificity: Specificity of a method can be defined as the into 100 mL volumetric flasks, dissolved in diluents and made absence of any interference at retention times of peaks of up to the mark with the mobile phase to get 200 ppm each of interest and is normally evaluated by observing the chromato- dapiprazole and its process related impurity solution. Transfer grams of blank samples and samples spiked with the API the 0.5 mL of the above stock solution and was adequately (active pharmaceutical ingredient) in the presence of all diluted up to 100 mL in volumetric flask with mobile phase to impurities in the mobile phase and the bulk drug. A separate get the concentration of 3 µg/mL (0.15 % level). solution of blank, standard and batch samples of dapiprazole Preparation of sample solutions: Samples of bulk drugs were evaluated along with impurity solutions. of dapiprazole (3 mg/mL) were prepared as by dissolving Linearity and range: The linearity of dapiprazole and 75 mg of dapiprazole in 25 mL volumetric flask containing its process related impurity was also studied by preparing diluents solution. standard solutions at seven different levels ranging from 0.75- N N CH3 N N .HCl NH N N Impurity-A: 1-(o-Tolyl)-piperizine Fig. 1. (a): Structures of dapiprazole and its impurity H3C O Cl + No2CO3 N CH3 O N CH3 ethyl 3-chloro-propionate NH O (I) 1-(o-tolyl)-piperozine O N Process related H3C Impurity-A ethyl 3-[4-(o-toly)-1-piperozinyl] propionate O Dapiprazole CH3 N H ·H Ob C H OH N CH I 2 4 2 2 5 N N 3 N CH Hydrozine hydrate 3 N N 6-methoxy-2,3,4,5-tetrohydropyridine N O HN N H2N 3-[4-(o-toly)-1-piperozinyl]propionate acid hydrazide Fig. 1. (b) Synthesis of dapiprazole 4822 Prasanthi et al. Asian J. Chem. 6 µg/mL. The data were subjected to statistical analysis using Forced degradation studies: Once the chromatographic a linear-regression model; the regression equations and coeffi- conditions were selected and the retention of dapiprazole was cients (r2) are given in calibration curves of dapiprazole and optimized, preliminary forced degradation studies were its process related impurity (o-tolyl piperizine) in Fig. 2. conducted using heat, acid and base hydrolysis, light and peroxide. The drug was exposed to extreme conditions to verify 450000 its stability under the conditions studied. To demonstrate the 400000 degradation of the sample in stress study, sample is prepared 350000 300000 and is evaluated at 0 h and after 48 h. 250000 Acid stress study: Weigh accurately and transfer ca. 300 200000 mg dapiprazole bulk sample in 20 mL of 0.1 N hydrochloric Y = 2113x + 3231 150000 R2 = 0.9998 acid. The 0 h-sample solution, has been prepared by taking 100000 Peak area/response immediately 5 mL of the above primary working standard 50000 0 solution and neutralize with 5 mL of 0.1 N sodium hydroxide 0.75 1.50 2.25 3.00 3.75 4.50 6.00 solution and makeup to 25 mL with diluents in volumetric Concentration (µµµg/mL) flask. The acid stress study sample after 48 h was prepared by taking the 5 mL of acid hydrolyzed sample solution in 25 mL 700000 volumetric flask and neutralize with 5 mL of 0.1 N NaOH 600000 solution and make up to 25 with diluent.
Load more

Recommended publications
  • Totalcare Medicaid 2017 Q2 GB
    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
    [Show full text]
  • Pharmacology of Ophthalmic Agents
    Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub
    US 2002O187986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub. Date: Dec. 12, 2002 (54) OPHTHALMIC FORMULATION WHICH Related U.S. Application Data MODULATES DILATION (62) Division of application No. 09/710,758, filed on Nov. (76) Inventor: Gerald Horn, Deerfield, IL (US) 8, 2000, now Pat. No. 6,420,407. Publication Classification Correspondence Address: Bell, Boyd & Lloyd LLC (51) Int. Cl." .................. A61K 31/517; A61K 31/4745; P.O. BOX 1135 A61K 31/4168; A61K 31/4164 Chicago, IL 60690 (US) (52) U.S. Cl. ..................... 514/252.17; 514/283; 514/401 (57) ABSTRACT (21) Appl. No.: 10/165,459 An ophthalmic formulation is disclosed which reduces dila (22) Filed: Jun. 7, 2002 tion in dim light and reduces redness. US 2002/0187986 A1 Dec. 12, 2002 OPHTHALMC FORMULATION WHICH 0007 A formulation for optimizing pupil size in extreme MODULATES DILATION lighting conditions is disclosed. The formulation is prefer ably a Solution of the type used in an artificial tear formu FIELD OF THE INVENTION lation having dissolved therein a therapeutically effective 0001. The present invention relates to a composition amount of a compound characterized by its ability to reduce formulated and administered to a human eye to reduce dilation of the eye, particularly in dim light. The compound dilation and redness. generally interferes with a natural biochemical reaction which results in the stimulation of the dilator muscles of the BACKGROUND OF THE INVENTION eye. The formulation is preferably further comprised of a compound which reduces eye redness, e.g.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Accommodation of Three Regimens of Topical Dapiprazole Br J Ophthalmol: First Published As 10.1136/Bjo.79.6.544 on 1 June 1995
    544 British Journal of Ophthalmology 1995; 79: 544-548 Comparison of the effects on pupil size and accommodation of three regimens of topical dapiprazole Br J Ophthalmol: first published as 10.1136/bjo.79.6.544 on 1 June 1995. Downloaded from Charles S Wilcox, Jon F Heiser, Anna Mae Crowder, Nancy J Wassom, Barbara B Katz, Jacqueline L Dale Abstract mydriasis induced by sympathomimetic Background-Patients who have their agents, such as phenylephrine, and parasympa- pupils dilated for an eye examination tra- tholytics, such as tropicamide, dapiprazole also ditionally have to wait several hours shows a beneficial effect on loss of accommo- before their pupils return to normal size dation,1 although the exact mechanism for its and their blurred vision (caused by paral- effect on accommodation is unknown. In most ysis of accommodation) resolves. Earlier patients, reversal of mydriasis and improve- studies with dapiprazole have demon- ment in accommodation begin within 15 strated an accelerated reversal of dilata- minutes of administration of the drug. tion. Since its introduction, dapiprazole has been Methods-Three regimens of dapiprazole used in a 2+2 regimen, two drops followed by were studied to determine the effects on two more drops 5 minutes later. In clinical pupil diameter and accommodation after practice, returning to dose the patient for a mydriasis produced by 2.5% phenyl- second time in 5 minutes can sometimes be ephrine and 0.5% tropicamide. Test troublesome for both the ophthalmologist and regimens included one drop and 1 + 1 the patient. After a review of the literature on drop regimens, compared with a 2 +2 drop dapiprazole, Doughty and Lyle2 suggested that reference regimen.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • PAPER SPRAY MASS SPECTROMETRY for RAPID DRUG SCREENING by Rachel Jett
    PAPER SPRAY MASS SPECTROMETRY FOR RAPID DRUG SCREENING by Rachel Jett A Thesis Submitted to the Faculty of Purdue University In Partial Fulfillment of the Requirements for the degree of Master of Science Department of Chemistry Indianapolis, Indiana August 2017 ii THE PURDUE UNIVERSITY GRADUATE SCHOOL STATEMENT OF COMMITTEE APPROVAL Dr. Nick Manicke, Chair Department of Chemistry and Chemical Biology Dr. John Goodpaster Department of Chemistry and Chemical Biology Dr. Michael McLeish Department of Chemistry and Chemical Biology Approved by: Dr. Eric C. Long Head of the Graduate Program iii To the Creator- Who places the mysteries of the world before us and the curiosities of the mind within us iv ACKNOWLEDGMENTS This project would not have been possible without the input, support, and feedback of the Manicke and Goodpaster Groups: Nick, Chengsen, Brandon, Greta, Josiah, Grace, John, Dana, Will, Jordan, Clinton Thank you. v TABLE OF CONTENTS LIST OF TABLES ........................................................................................................... viii LIST OF FIGURES ............................................................................................................ x LIST OF ABBREVIATIONS .......................................................................................... xiv ABSTRACT ................................................................................................................. xv CHAPTER 1: BACKGROUND ........................................................................................
    [Show full text]